E4/DRSP Ovarian Function Inhibition Study

PHASE2CompletedINTERVENTIONAL
Enrollment

82

Participants

Timeline

Start Date

February 7, 2017

Primary Completion Date

June 8, 2018

Study Completion Date

June 8, 2018

Conditions
Prevention of Pregnancy
Interventions
DRUG

15 mg E4/3 mg DRSP

15 mg E4/3 mg DRSP combined tablets will be administered orally once daily in a 24/4 day regimen for three consecutive cycles

DRUG

20 mcg EE/3 mg DRSP

20 mcg EE/3 mg DRSP combined tablets will be administered orally once daily in a 24/4 day regimen for three consecutive cycles

Trial Locations (1)

9713 CZ

Dinox BV, Groningen

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Estetra

INDUSTRY

NCT03091595 - E4/DRSP Ovarian Function Inhibition Study | Biotech Hunter | Biotech Hunter